Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | QQQE | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $122.72 |
52-Week Low | $0.48 | $96.06 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $123.14, up 0.81% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 companies, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the index, which could drive additional inflows. Technical indicators show strong momentum with ADX readings above 25, though RSI suggests some overbought conditions near-term.
The equal-weight approach offers defensive positioning against tech concentration risks while maintaining Nasdaq growth exposure. Key catalysts include continued tech sector strength and index rebalancing benefits. Risks involve Nasdaq volatility and potential sector rotation away from growth stocks. The ETF's structure provides diversification benefits for investors seeking balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
